Adriana Carluccio Hasher

Rheumatic diseases affect millions of people around the world and can cause significant pain, disability, and reduced quality of life. In 2023, the global situation regarding rheumatic diseases remains a major public health challenge.

Rheumatic diseases refer to a group of conditions that affect the joints, bones, muscles, and other connective tissues. They can cause inflammation, pain, stiffness, and joint deformities, among other symptoms. The most common rheumatic diseases include osteoarthritis, rheumatoid arthritis, lupus, gout, and fibromyalgia.

According to the World Health Organization (WHO), over 10% of the world’s population is affected by a rheumatic disease. The prevalence of rheumatic diseases varies across countries and regions, but they are more common in low- and middle-income countries, where access to healthcare and treatment is often limited.

In 2023, the COVID-19 pandemic continues to impact the global situation of rheumatic diseases. People with rheumatic diseases are considered to be at higher risk of severe COVID-19 disease and complications, especially those who are older or have comorbidities. The pandemic has also disrupted healthcare services and access to treatment for people with rheumatic diseases.

In some countries, access to rheumatology services, including diagnosis, treatment, and follow-up care, remains a challenge due to limited resources, inadequate healthcare infrastructure, and a shortage of rheumatologists. In other countries, the high cost of medications and treatments is a major barrier to care.

However, there have been some positive developments in the world situation regarding rheumatic diseases in 2023. Advances in research have led to the development of new treatments and therapies that can help manage symptoms and improve quality of life for people with rheumatic diseases. These include biologic therapies, gene therapies, and other targeted therapies.

There is also increasing recognition of the importance of early diagnosis and treatment for rheumatic diseases. Screening programs and public awareness campaigns have been launched in some countries to promote early detection and referral to rheumatology services.

Moreover, patient advocacy groups and organizations have been working to raise awareness about rheumatic diseases and to advocate for better access to care, treatment, and support for people with these conditions.

In conclusion, while rheumatic diseases continue to be a significant public health challenge in 2023, there are reasons for hope. Advances in research, increased awareness, and advocacy efforts are all contributing to improving the world situation regarding rheumatic diseases. However, there is still a long way to go in ensuring that all people with rheumatic diseases have access to the care and treatment they need to manage their condition and improve their quality of life.